Business
Candel Therapeutics Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110
CAN-3110 is a first-in-class herpes simplex virus-1 oncolytic immunotherapy candidate with dual activity for oncolysis and immune activation in a single
About this update from Candel Therapeutics, Inc.
[{"type":"text","content":"CAN-3110 is a first-in-class herpes simplex virus-1 oncolytic immunotherapy candidate with dual activity for oncolysis and immune activation in a single therapeuticIn a first-in-human clinical trial of CAN-3110 in recurrent high-grade glioma, CAN-3110 was well tolerated and treatment was associate with improved survivalPositive HSV-1 serology, before or after CAN-3110 injection, was a predictor of response and was associated with improved survivalIncreased infiltrating immune cells in the tumor microenvironment and expansion of the T cell repertoire after treatment were associated with improved survival NEEDHAM, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (the Company or Candel) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced that Nature published results from the ongoing first-in-human phase 1 investigator-sponsored clinical trial of CAN-3110, a first-in-class, replication-competent herpes simplex virus-1 (HSV-1) oncolytic viral immunotherapy candidate, in patients with recurrent high-grade glioma (HGG), of which 86.7% were glioblastoma, that had returned after standard of care (SoC) treatment. The study is being conducted in a collaboration between Brigham and Women’s Hospital and Candel. The publication titled “Clinical trial links oncolytic immunoactivation to survival in glioblastoma” can be accessed here. Key findings of the manuscript: Tolerability of a single injection of CAN-3110 in recurrent HGG with no dose limiting toxicity reported, improved median overall survival in 41 patients treated in Arm A (11.6 months as of data cutoff in October 2022) and correlation between anti-HSV-1 serology and survival. Importantly, CAN-3110 treatment was associated with a significant increase in immune cells in the tumor microenvironment and in the peripheral blood. The activation of both local and systemic immune response, including the expansion of the T-cell repertoire diversity as well as HSV-1 immune status, correlate with survival suggesting that CAN-3110 can enhance anti-cancer immune responses even in immunosuppressive tumor microenvironments. “There is an urgent need to develop novel therapies for recurrent HGG,” said E. Antonio Chiocca, MD, PhD, Head of Department of Neurosurgery at Brigham and Women’s...